Tamoxifen, the first ER modulator has reduced breast cancer recurrence and annual mortality rate by 50% and 31%, respectively, since the approval by the Food and Drug Administration (FDA) for the treatment of women with advanced breast cancer [11]. Here, ESR1 is linked to breast carcinoma.